Sentences with phrase «for prostate cancer research»

Santa Monica, CA About Blog The Prostate Cancer Foundation (PCF) is the world's largest philanthropic source of support for prostate cancer research to discover better treatments and cures for prostate cancer.

Prostate Cancer Foundation - Curing Together Santa Monica, CA About Blog The Prostate Cancer Foundation (PCF) is the world's largest philanthropic source of support for prostate cancer research to discover better treatments and cures for...

CUA is also highly involved in community events, including the sponsorship of the Zero Prostate Cancer Challenge, a 5K / 10K run that raises awareness and money for prostate cancer research.

-LCB- module Nova Scotia judges, lawyers raise over $ 90K for Movember -RCB--LCB- nomultithumb -RCB- Nova Scotia's legal community raised more than $ 90,000 for prostate cancer research through its Movember campaign.

Congratulations to all the participants who have been instrumental in helping Canada raise mo» than any other country in the world — for the second year in a row — during the Movember campaing for prostate cancer research and men's mental health.

Santa Monica, CA About Blog The Prostate Cancer Foundation (PCF) is the world's largest philanthropic source of support for prostate cancer research to discover better treatments and cures for prostate cancer.

This year, the American Cancer Society has earmarked approximately $ 7.5 million dollars for prostate cancer research.

Santa Monica, CA About Blog The Prostate Cancer Foundation (PCF) is the world's largest philanthropic source of support for prostate cancer research to discover better treatments and cures for prostate cancer.

3/9/2007 Prostate Cancer Foundation Awards $ 100K to UCSD Researcher The Prostate Cancer Foundation (PCF), the world's largest philanthropic source of support for prostate cancer research, has granted Michael G. Rosenfeld, M.D., an internationally known and respected molecular biologist, a $ 100,000 award as part of th... More...

Dr. Sharifi holds positions in Cleveland Clinic's Lerner Research Institute, Glickman Urological & Kidney Institute, and Taussig Cancer Institute, and is the Kendrick Family Endowed Chair for Prostate Cancer Research.

Not exact matches

NEW YORK (360Dx)-- Biotech firm Berg continued its push into cancer diagnostics with the presentation of several posters earlier this month at the annual meeting of the American Association for Cancer Research and the preparation of a forthcoming publication detailing an assay for distinguishing between prostate cancer and benign prostate hyperpcancer diagnostics with the presentation of several posters earlier this month at the annual meeting of the American Association for Cancer Research and the preparation of a forthcoming publication detailing an assay for distinguishing between prostate cancer and benign prostate hyperpCancer Research and the preparation of a forthcoming publication detailing an assay for distinguishing between prostate cancer and benign prostate hyperpcancer and benign prostate hyperplasia.

For instance, research has shown that combining cauliflower with curcumin (the active compound in the spice turmeric) may help prevent and treat prostate cancer.1

The results from the Cancer Research UK - funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first - line treatment alongside hormone thCancer Research UK - funded STAMPEDE trial could change the standard of care for men with prostate cancer, making abiraterone a first - line treatment alongside hormone thcancer, making abiraterone a first - line treatment alongside hormone therapy.

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRFor men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRfor extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRfor Radiation Oncology (ASTRO).

Looking to target a key pathway in order to interfere with the processes that lead to tumor spread, a research team led by Irwin H. Gelman, Ph.D., of Roswell Park Cancer Institute (RPCI) has identified a new suppressor of cancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tCancer Institute (RPCI) has identified a new suppressor of cancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tcancer metastasis that may point the way toward development of more effective treatments for prostate cancers and other malignant solid tumors.

The findings could shake up prostate cancer research, providing targets for treatment, diagnosis and monitoring of one of the most prevalent cancers in the west.

Cancer Research UK is funding work that will allow us to follow the men for at least a further five years to see whether there is any longer - term benefit on reducing prostate cancer deaths.&Cancer Research UK is funding work that will allow us to follow the men for at least a further five years to see whether there is any longer - term benefit on reducing prostate cancer deaths.&cancer deaths.»

For example, we're funding research into faulty genes which make some men more likely to develop prostate cancer and studying how these genes could help doctors to identify patients who are more at risk.

The findings could shake up prostate cancer research, providing targets for treatment of one of the most prevalent cancers in the west.

Cancer Research UK's hunt for finding early stages of aggressive prostate cancer is notCancer Research UK's hunt for finding early stages of aggressive prostate cancer is notcancer is not over.

Much like the association between BRCA gene mutation and the risk for breast cancer in women changed the approach to treatment / prevention, the identification of the Kallikrein 6 gene region may change the course of prostate cancer care through a blood test developed by the Lunenfeld - Tanenbaum Research Institute.

«Genes may cause tumor aggressiveness, drug resistance in African - American prostate cancer: Research found many targeted therapies for prostate cancer may not be effective against tumors in African - American men.»

«Prostate cancers only kill men after they have spread or «metastasised» from the prostate,» says project leader Dr Luke Selth, Senior Research Fellow at the University of Adelaide's Dame Roma Mitchell Cancer Research Laboratories and a member of the Freemasons Foundation Centre for Men'sProstate cancers only kill men after they have spread or «metastasised» from the prostate,» says project leader Dr Luke Selth, Senior Research Fellow at the University of Adelaide's Dame Roma Mitchell Cancer Research Laboratories and a member of the Freemasons Foundation Centre for Men'sprostate,» says project leader Dr Luke Selth, Senior Research Fellow at the University of Adelaide's Dame Roma Mitchell Cancer Research Laboratories and a member of the Freemasons Foundation Centre for Men's Health.

In 2009 the nongovernmental Institute of Medicine (IOM) released a list of 100 disorders, including lower back pain, atrial fibrillation, and early prostate cancer, that it says require research analyzing which treatments work best for different groups of patients.

David Agus, the research director of the Louis Warschaw Prostate Cancer Center and director of the Spielberg Family Center for Applied Proteomics, both at Cedars - Sinai Medical Center in Los Angeles, spent most of his time with end - of - life cancer patCancer Center and director of the Spielberg Family Center for Applied Proteomics, both at Cedars - Sinai Medical Center in Los Angeles, spent most of his time with end - of - life cancer patcancer patients.

She now heads the Laboratory for Human Comparative and Prostate Cancer Genomics at Sydney's Garvan Institute of Medical Research.

Center for Nuclear Receptors & Cell Signaling (CNRCS) Assistant Professor Daniel Frigo and his research team recently published a study investigating the processes through which androgen receptors affect prostate cancer progression.

Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said, «Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaCancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said, «Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaCancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said, «Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olacancer cells to become resistant to the precision medicine olaparib.

The researchers, at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, say their test is the first developed for a precision prostate cancer therapy targeted at specific genetic faults within tuCancer Research, London, and The Royal Marsden NHS Foundation Trust, say their test is the first developed for a precision prostate cancer therapy targeted at specific genetic faults within tucancer therapy targeted at specific genetic faults within tumours.

It was funded by the Prostate Cancer Foundation, Prostate Cancer UK, Movember, Cancer Research UK and the National Institute for Health Research (NIHR) via the Experimental Cancer Medicine Centre network, and the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (ICR).

Nearly three years of research have brought about remarkable results for the majority of 80 patients subjected to targeted alpha therapy of metastatic prostate cancer.

A relatively new biomarker called prostate - specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Recently published in the journal eLife and featured in a poster session at this year's American Association for Cancer Research (AACR) annual meeting, preclinical experiments show for the first time that PLK1 promotes the migration of prostate cancer cells by setting in motion a process that induces what is known as the epithelial - to - mesenchymal transition Cancer Research (AACR) annual meeting, preclinical experiments show for the first time that PLK1 promotes the migration of prostate cancer cells by setting in motion a process that induces what is known as the epithelial - to - mesenchymal transition cancer cells by setting in motion a process that induces what is known as the epithelial - to - mesenchymal transition (EMT).

The new research could lead to a change in the way treatment decisions are made for prostate cancer patients.

«Our research provides the first direct evidence that exposure to BPA during development, at the levels we see in our day - to - day lives, increases the risk for prostate cancer in human prostate tissue,» Prins said.

The study, which appears online June 1, 2015 in the journal Cancer Prevention Research, offers insight on how diet may help improve survivorship for the nearly three million men living with prostate cancer in thCancer Prevention Research, offers insight on how diet may help improve survivorship for the nearly three million men living with prostate cancer in thcancer in the U.S.

Detailed evaluation of a prostate cancer tumor biopsy may predict treatment outcomes for image - guided radiation therapy (IGRT) or surgery for prostate cancer, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

The gap was scarcely any narrower for Britain's third biggest cancer charity, the Cancer Research Campaign (CRC), which spent Pounds sterling 250 000 on prostate cancer research and Pounds sterling 3.6 million on breast cancer procancer charity, the Cancer Research Campaign (CRC), which spent Pounds sterling 250 000 on prostate cancer research and Pounds sterling 3.6 million on breast cancer proCancer Research Campaign (CRC), which spent Pounds sterling 250 000 on prostate cancer research and Pounds sterling 3.6 million on breast cancer pResearch Campaign (CRC), which spent Pounds sterling 250 000 on prostate cancer research and Pounds sterling 3.6 million on breast cancer procancer research and Pounds sterling 3.6 million on breast cancer presearch and Pounds sterling 3.6 million on breast cancer procancer projects.

The ICGC Prostate Cancer UK group — funded by Cancer Research UK, the Dallaglio Foundation, the Wellcome Trust, the Academy of Finland and others — is examining how the disease evolves in patients to help develop approaches for personalised medicine, tailored to the genetic makeup of each person's cCancer UK group — funded by Cancer Research UK, the Dallaglio Foundation, the Wellcome Trust, the Academy of Finland and others — is examining how the disease evolves in patients to help develop approaches for personalised medicine, tailored to the genetic makeup of each person's cCancer Research UK, the Dallaglio Foundation, the Wellcome Trust, the Academy of Finland and others — is examining how the disease evolves in patients to help develop approaches for personalised medicine, tailored to the genetic makeup of each person's cancercancer.

Detailed evaluation of a prostate cancer tumor biopsy may predict treatment outcomes for image - guided radiation therapy (IGRT) or surgery for prostate cancer, according to research presented at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

Baltimore, Md. (Embargoed until 12:30 pm EDT on Monday, June 8)-- A relatively new biomarker called prostate - specific membrane antigen (PSMA) is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types, according to research unveiled at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

«Therapies for metastatic prostate cancer are urgently needed,» said Dr. Owen Witte, founding director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, university professor of microbiology, immunology and molecular genetics at the UCLA David Geffen School of Medicine, and a senior author of the paper.

Radiotherapy given in high doses over a shorter period of time is safe and effective for prostate cancer patients, according to research presented at the ESTRO 37 conference today.

Published in the May 1 edition of Cancer Research, the study supports a critical role for IGF - 1R signaling in prostate - tumor development and identifies an important IGF - 1R - dependent growth control mechanism, according to the authors.

Professor de Bono's research will be instrumental in meeting the urgent need for better prostate cancer treatments that will help more men survive the disease.

Barcelona, Spain: Radiotherapy given in high doses over a shorter period of time is safe and effective for prostate cancer patients, according to research presented at the ESTRO 37 conference today.

With enthusiasm for cancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sCancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patientsResearch Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sCancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients scancer treatment and of the need for continued public support for research to bring these treatments to more patientsresearch to bring these treatments to more patients sooner.

The research evidence on breast, colorectal (bowel), pancreatic, endometrial (womb), ovarian, prostate, liver, gallbladder, kidney, bladder, stomach and oesophageal cancers has been updated as part of our Continuous Update Project (CUP); these CUP reports replace the conclusions for these cancers from the Second Expert Report.

He gave $ 25 million to fund research and develop a new prostate and urological cancer center at Memorial Sloan - Kettering Cancer Center in New York City, and he has made significant gifts for cancer research in San Diego and Philadecancer center at Memorial Sloan - Kettering Cancer Center in New York City, and he has made significant gifts for cancer research in San Diego and PhiladeCancer Center in New York City, and he has made significant gifts for cancer research in San Diego and Philadecancer research in San Diego and Philadelphia.

His most recently awarded grants are from the Agency for Health Care Research and Quality, where he is Co-PI of the program project grant, «Eliminating Racial Disparities in Health,» and from the Centers for Disease Control where he is PI of a constituent case - case project comparing prostate cancer outcomes among African Americans and Caucasians.